Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane

British Journal of Cancer

Volumn 89, Issue 2, 2003, Pages 262-267

  Anderson, H ^a   Yap, J T ^a   Wells, P ^a   Miller, M P ^a   Propper, D ^b   Price, P ^a,c   Harris, A L ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Antiangiogenic; Positron emission tomography; Razoxane; Tumour perfusion

Indexed keywords

ANGIOGENESIS INHIBITOR; RAZOXANE;

ANGIOGENESIS; ARTICLE; BLOOD VOLUME; CANCER PATIENT; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; METASTASIS INHIBITION; MUSCLE PERFUSION; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CARBON MONOXIDE; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN RADIOISOTOPES; RAZOXANE; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED; WATER;

EID: 0042622316     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601105     Document Type: Article

References (25)

1. Anderson H, Price P (2002) Blood flow in tumours using PET: a review. Nucl Med Commun 23: 131-138
2. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a Phase I Trial of combretastatin A4 phosphate. J Clin Oncol (in press)
3. Araujo LI, Lammerstma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, Galassi A, De Silva R, Jones T, Maseri A (1991) Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation 83: 875-885
4. Bakowski MT (1976) ICRF 159, (+1-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. Cancer Treat Rev 3: 95-107
5. Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60: 1395-1397
6. Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, Ebrahimnejad A, Dohrmann P, Kalthoff H, Henne-Bruns D, Neumaier M (2001) Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 94: 420-428
7. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL (2000) A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of antiangiogenesis. Clin Cancer Res 6: 4697-4704
8. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255-1262
9. DeKernion JB (1986) Renal tumors. In Campbell's Urology, Walsh PC, Gittes RF, Perlmutter AD (eds) pp 1294-1342. Philadelphia: W.B. Saunders
10. Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224: 273-275
11. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim H-W, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804-3814
12. Lammertsma AA, Wise RJ, Cox TC, Thomas DG, Jones T (1985) Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. Br J Radiol 58: 725-734
13. Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. BMJ 4: 597-601
14. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB (2002) Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43: 500-509
15. Meyer AJ, Hernandez A, Florl AR, Enczmann J, Gerharz CD, Schulz WA, Wernet P, Ackermann R (2000) Novel mutations of the von Hippel-Lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type. Int J Cancer 87: 650-653
16. O'Connell MJ, Begg CB, Silverstein MN, Glick JH, Oken MM (1980) Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas. Cancer Treat Rep 64. 1355-1358
17. Ohh M, Kaelin WG (1999) The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today 5: 257-263
18. Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T (1991) The on-line monitoring of continuously withdrawn arterial blood during PET studies using a BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 17: 259-264
19. Salsbury AJ, Burrage K, Hellmann K (1970) Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. BMJ 4: 344-346
20. Salsbury AJ, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res 34: 843-849
21. Sasaki R (1996) Microvessel count and vascular endothelial growth factor in renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi 87: 1032-1040
22. Sharpe HB, Field EO, Hellmann K (1970) Mode of action of the cytostatic agent 'ICRF 159'. Nature 226: 524-526
23. Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, Hoshima M, Takahashi T (1996) Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 37: 1522-1523
24. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2472-2484
25. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 52: 1592-1597